Nutriband Inc. (NTRB) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2027, filed Sep 4, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the NTRB SEC filings page.
Nutriband Inc. (NTRB) reported $2.0M in revenue for fiscal year 2026, down 4.8% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Nutriband’s small revenue base is overwhelmed by operating costs, leaving recurring cash needs funded largely through financing rather than operations.
Across FY2024-FY2026, revenue stayed around$2.0M while operating cash outflow reached$5.1M in FY2026, indicating the cost base expanded without a larger sales base to absorb it. FY2026 financing inflows of$5.4M were roughly equal to that operating outflow, so liquidity is being supported externally rather than generated internally.
Margin deterioration and overhead scale are reinforcing each other: gross margin fell from
The current ratio improved from 1.0x to 6.4x between FY2024 and FY2026, but shares outstanding also increased by about 1.0M while FY2026 financing supplied
Financial Health Signals
Scored against emerging companies for FY2026. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Nutriband Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Nutriband Inc. held $4.6M in cash, cash equivalents and investments at the end of fiscal year 2026, and its operations used $5.1M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Nutriband Inc. scores 31/100 among other emerging companies.
Nutriband Inc. had 12M shares outstanding at the end of fiscal year 2026. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Nutriband Inc. scores 57/100 among other emerging companies.
Nutriband Inc. spent $1.9M on research and development in fiscal year 2026, which was 18.3% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Nutriband Inc. scores 49/100 among other emerging companies.
Nutriband Inc. reported revenue of $2.0M in fiscal year 2026, against $2.1M in fiscal year 2025. Revenue Progress ranks emerging companies on the three-year path of that line, and Nutriband Inc. scores 43/100 among other emerging companies.
Nutriband Inc.'s operations used $5.1M of cash in fiscal year 2026, against $4.6M used in fiscal year 2025. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Nutriband Inc. scores 30/100 among other emerging companies.
Nutriband Inc.'s cash, cash equivalents and investments came to $4.6M at the end of fiscal year 2026, against $868K of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Nutriband Inc. scores 90/100 among other emerging companies.
Nutriband Inc. scores 44.49, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($80.8M) relative to total liabilities ($868K). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Nutriband Inc. passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
Nutriband Inc. reported a net loss of $8.2M while operations used $5.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Nutriband Inc. reported an operating loss of $8.3M against $23K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Nutriband Inc. generated $438K in revenue in Q2 2027. This represents a decrease of 29.7% from the same quarter a year earlier. Against the prior quarter it is up 0.9%.
Nutriband Inc.'s EBITDA was -$857K in Q2 2027, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 55.9% from the same quarter a year earlier. Against the prior quarter it is up 29.7%.
Nutriband Inc. reported -$881K in net income in Q2 2027. This represents an increase of 56.0% from the same quarter a year earlier. Against the prior quarter it is up 29.1%.
Nutriband Inc. earned -$0.07 per diluted share (EPS) in Q2 2027. Against the prior quarter it is up 30.0%.
Cash & Balance Sheet
Nutriband Inc. held $3.4M in cash as of Q2 2027; long-term debt is not reported for that period.
Not reported for Q2 2027.
Not reported for Q2 2027.
Margins & Returns
Nutriband Inc.'s gross margin was 41.6% in Q2 2027, indicating the percentage of revenue retained after direct costs. This is up 16.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 3.8 percentage points.
Nutriband Inc.'s ROE was -16.5% in Q2 2027, measuring profit generated per dollar of shareholder equity. This is up 7.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 4.2 percentage points.
Not shown for Q2 2027: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2027: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Nutriband Inc. invested $322K in research and development in Q2 2027. This represents a decrease of 42.7% from the same quarter a year earlier. Against the prior quarter it is up 30.3%.
Not reported for Q2 2027.
Not reported for Q2 2027.
NTRB Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2710-Q | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $438K-29.7% | $433K-35.1% | $401K-37.6% | $346K-46.4% | $622K+40.6% | $667K+63.4% | $642K+22.4% | $646K+50.9% |
| Cost of Revenue | $256K-45.1% | $237K-43.1% | $312K-12.5% | $278K-39.0% | $466K+36.4% | $415K+70.4% | $356K-32.1% | $455K+6.3% |
| Gross Profit | $182K+15.9% | $197K-21.9% | $89K-68.9% | $69K-64.1% | $157K+54.5% | $252K+52.9% | $286K-12.5% | $191K+19.6% |
| R&D Expenses | $322K-42.7% | $247K-63.8% | $188K-61.6% | $457K-48.1% | $563K-27.3% | $683K-29.9% | $490K-13.0% | $881K+59.7% |
| SG&A Expenses | $750K-53.0% | $1.2M+22.6% | $922K-47.6% | $3.5M+373.7% | $1.6M+116.7% | $982K-9.0% | $1.8M+90.4% | $737K-44.6% |
| Operating Income | -$891K+55.5% | -$1.3M+11.3% | -$1.0M+81.6% | -$3.9M-172.0% | -$2.0M-42.1% | -$1.4M+25.2% | -$5.6M-325.5% | -$1.4M+17.2% |
| EBITDA | -$857K+55.9% | -$1.2M+10.0% | -$985K+82.0% | -$3.8M-183.5% | -$1.9M-45.2% | -$1.4M+25.5% | -$5.5M-343.7% | -$1.4M+18.3% |
| Interest Expense | $5K-15.6% | $5K+96.5% | $9K-11.4% | $6K+37.6% | $6K+15.0% | $3K-1.1% | $10K-57.9% | $4K-90.0% |
| Net Income | -$881K+56.0% | -$1.2M+10.6% | -$968K+82.5% | -$3.9M-184.2% | -$2.0M-17.3% | -$1.4M+26.8% | -$5.5M-193.3% | -$1.4M+22.6% |
| EPS (Basic) | -$0.07+96.7% | -$0.10+16.7% | -$0.04+92.2% | -$0.32-166.7% | -$2.12-1313.3% | -$0.12+42.9% | -$0.51-121.7% | -$0.12+45.5% |
| EPS (Diluted) | -$0.07 | -$0.10+16.7% | -$0.04 | -$0.32-166.7% | -$2.12 | -$0.12+42.9% | -$0.51-121.7% | -$0.12+45.5% |
| Diluted Shares (Avg) | 12M | 12M+9.3% | N/A | 12M+8.6% | 11M | 11M+21.5% | N/A | 11M+41.7% |
Not reported in any period shown, so not listed: Income Tax.
NTRB Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2710-Q | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $6.3M-38.2% | $6.9M+12.0% | $7.5M+1.0% | $8.4M-32.9% | $10.2M-25.4% | $6.2M-59.4% | $7.5M-0.6% | $12.5M+47.2% |
| Current Assets | $3.8M-49.2% | $4.4M+27.6% | $5.0M+4.1% | $5.8M-6.1% | $7.5M+3.8% | $3.4M-60.7% | $4.8M+369.2% | $6.2M+209.6% |
| Cash & Equivalents | $3.4M-51.1% | $4.0M+35.2% | $4.6M+6.1% | $5.3M-6.8% | $7.0M+3.5% | $3.0M-64.5% | $4.3M+774.7% | $5.7M+350.3% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $171K+23.7% | $121K-43.6% | $118K-44.4% | $136K-19.2% | $138K-38.3% | $215K+27.8% | $212K+25.8% | $168K-3.6% |
| Accounts Receivable | $24K-85.3% | $3K-97.2% | $118K+60.3% | $148K+34.6% | $161K+136.4% | $94K+10.6% | $74K-50.3% | $110K-35.4% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $1.7M0.0% | $1.7M0.0% | $1.7M0.0% | $1.7M-65.8% | $1.7M-65.8% | $1.7M-65.8% | $1.7M-65.8% | $5.0M0.0% |
| Total Liabilities | $964K-42.7% | $902K-14.0% | $868K-16.6% | $870K-33.6% | $1.7M+43.5% | $1.0M-41.5% | $1.0M-3.5% | $1.3M-53.4% |
| Current Liabilities | $907K-42.3% | $832K-10.0% | $784K-20.2% | $773K-38.1% | $1.6M+42.4% | $925K-34.7% | $983K-1.6% | $1.2M+73.8% |
| Non-Current Liabilities | $57K-48.4% | $70K-43.3% | $84K+44.6% | $98K+53.3% | $111K+60.5% | $124K-67.0% | $58K-27.1% | $64K-97.0% |
| Total Equity | $5.3M-37.3% | $6.0M+17.4% | $6.7M+3.9% | $7.5M-32.8% | $8.5M-31.8% | $5.1M-61.8% | $6.4M-0.1% | $11.2M+96.7% |
| Retained Earnings | -$48.8M-16.6% | -$47.9M-20.3% | -$46.7M-21.4% | -$45.7M-38.8% | -$41.9M-32.5% | -$39.9M-33.4% | -$38.5M-37.5% | -$32.9M-26.2% |
Not reported in any period shown, so not listed: Long-Term Debt.
NTRB Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2710-Q | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$585K+55.5% | -$563K+57.9% | -$732K+40.9% | -$1.8M-73.6% | -$1.3M+14.9% | -$1.3M-60.3% | -$1.2M-72.5% | -$1.0M+5.1% |
| Depreciation & Amortization | $33K-41.9% | $34K-40.5% | $36K-50.8% | $43K-41.3% | $57K-18.0% | $57K-16.8% | $73K+5.1% | $73K+8.7% |
| Stock-Based Compensation | N/A | $552K | N/A | N/A | N/A | N/A | N/A | N/A |
| Capital Expenditures | N/A | N/A | $0 | $0-100.0% | $0-100.0% | $5K-14.1% | $0-100.0% | $47K |
| Free Cash Flow | N/A | N/A | -$732K+40.9% | -$1.8M-65.9% | -$1.3M+17.0% | -$1.3M-59.8% | -$1.2M-61.5% | -$1.1M+0.7% |
| Investing Cash Flow | N/A | N/A | $0 | $0+100.0% | $0+100.0% | -$5K+14.1% | $0+100.0% | -$47K |
| Financing Cash Flow | $430-100.0% | -$6K-4.6% | -$5K+96.3% | $70K+1444.2% | $5.3M+104156.5% | -$5K-100.1% | -$147K-2842.1% | -$5K-4.3% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
NTRB Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2710-Q | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 41.6%+16.4pp | 45.4%+7.7pp | 22.2%-22.3pp | 19.8%-9.8pp | 25.2%+2.3pp | 37.8%-2.6pp | 44.5%-17.8pp | 29.6%-7.8pp |
| Operating Margin | -203.6% | -289.4% | -254.8% | -1121.3% | -321.8% | -211.8% | -865.3% | -220.9% |
| Net Margin | -201.3% | -286.6% | -241.6% | -1119.0% | -321.4% | -208.1% | -858.8% | -211.0% |
| Return on Equity | -16.5%+7.0pp | -20.7%+6.5pp | -14.5%+71.3pp | -51.3%-39.2pp | -23.5%-9.9pp | -27.2%-13.0pp | -85.8%-56.6pp | -12.1%+18.7pp |
| Return on Assets | -14.0%+5.7pp | -18.0%+4.6pp | -12.8%+61.0pp | -46.0%-35.1pp | -19.7%-7.2pp | -22.6%-10.1pp | -73.9%-48.8pp | -10.9%+9.8pp |
| Current Ratio | 4.21-0.6x | 5.26+1.6x | 6.36+1.5x | 7.53+2.6x | 4.78-1.8x | 3.71-2.5x | 4.88+3.9x | 4.96+2.2x |
| Debt-to-Equity | 0.180.0x | 0.15-0.1x | 0.130.0x | 0.120.0x | 0.20+0.1x | 0.21+0.1x | 0.160.0x | 0.12-0.4x |
| Asset Turnover | 0.070.0x | 0.060.0x | 0.050.0x | 0.040.0x | 0.060.0x | 0.11+0.1x | 0.090.0x | 0.050.0x |
| FCF Margin | N/A | N/A | -182.6% | -506.4% | -211.0% | -201.1% | -192.9% | -163.6% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Nutriband Inc. NTRB | FY2026 | $2.0M | -$8.2M | N/A | $80.8M | 50/100 |
| Sutro Biopharma, Inc. STRO | FY2025 | $102.5M | -$191.0M | N/A | $236.6M | 48/100 |
| OKYO Pharma Limited OKYO | FY2025 | N/A | -$4.7M | N/A | $74.5M | — |
| Cel-Sci Corporation CVM | FY2025 | N/A | -$25.4M | N/A | $34.1M | — |
| XBiotech Inc XBIT | FY2025 | N/A | -$45.5M | N/A | $69.8M | — |
| Quince Therapeutics, Inc. QNCX | FY2025 | N/A | -$84.0M | N/A | $32.3M | — |
Where Nutriband Inc. Ranks
Frequently Asked Questions
What is Nutriband Inc.'s annual revenue?
Nutriband Inc. (NTRB) reported $2.0M in total revenue for fiscal year 2026. This represents a -4.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Nutriband Inc.'s revenue growing?
Nutriband Inc. (NTRB) revenue declined by 4.8% year-over-year, from $2.1M to $2.0M in fiscal year 2026.
Is Nutriband Inc. profitable?
No, Nutriband Inc. (NTRB) reported a net income of -$8.2M in fiscal year 2026.
What is Nutriband Inc.'s EBITDA?
Nutriband Inc. (NTRB) had EBITDA of -$8.1M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.
What is Nutriband Inc.'s gross margin?
Nutriband Inc. (NTRB) had a gross margin of 27.8% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.
What is Nutriband Inc.'s return on equity (ROE)?
Nutriband Inc. (NTRB) has a return on equity of -123.2% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.
What is Nutriband Inc.'s free cash flow?
Nutriband Inc. (NTRB) recorded an outflow of $5.1M in free cash flow during fiscal year 2026. This represents a -8.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Nutriband Inc.'s operating cash flow?
Nutriband Inc. (NTRB) recorded an outflow of $5.1M in operating cash flow during fiscal year 2026, representing cash used by core business activities.
What are Nutriband Inc.'s total assets?
Nutriband Inc. (NTRB) had $7.5M in total assets as of fiscal year 2026, including both current and long-term assets.
What are Nutriband Inc.'s capital expenditures?
Nutriband Inc. (NTRB) invested $5K in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.
How much does Nutriband Inc. spend on research and development?
Nutriband Inc. (NTRB) invested $1.9M in research and development during fiscal year 2026.
What is Nutriband Inc.'s current ratio?
Nutriband Inc. (NTRB) had a current ratio of 6.36 as of fiscal year 2026, which is generally considered healthy.
What is Nutriband Inc.'s debt-to-equity ratio?
Nutriband Inc. (NTRB) had a debt-to-equity ratio of 0.13 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Nutriband Inc.'s return on assets (ROA)?
Nutriband Inc. (NTRB) had a return on assets of -109.0% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
What is Nutriband Inc.'s P/E ratio?
Nutriband Inc. (NTRB) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to July 31, 2026). The market capitalization is $80.8M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Nutriband Inc.'s price-to-sales ratio?
Nutriband Inc. (NTRB) trades at 50.0x sales, its market capitalization divided by revenue of $1.6M revenue, trailing 12 months to July 31, 2026. The market capitalization is $80.8M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Nutriband Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2026, Nutriband Inc. (NTRB) held $4.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $5.1M over that year. Dividing the one by the other, the reported balance equals about 11 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Nutriband Inc.'s Altman Z-Score?
Nutriband Inc. (NTRB) has an Altman Z-Score of 44.49, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Nutriband Inc.'s Piotroski F-Score?
Nutriband Inc. (NTRB) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Nutriband Inc.'s earnings high quality?
Nutriband Inc. (NTRB) reported a net loss of $8.2M while operations used $5.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Nutriband Inc. cover its interest payments?
Nutriband Inc. (NTRB) reported an operating loss of $8.3M against $23K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Nutriband Inc.?
Nutriband Inc. (NTRB) scores 50 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.